Agarwal Gautum, Sharma Pranav, Valderrama Oscar, Lin Hui-Yi, Yue Binglin, Nguyen Sabine, Fishman Mayer, Luchey Adam, Pow-Sang Julio M, Spiess Philippe E, Poch Michael A, Sexton Wade J
Departments of Genitourinary Oncology, and Biostatistics and Bioinformatics (HYL, BY), Moffitt Cancer Center, Tampa, Florida.
Urol Pract. 2017 Jan;4(1):36-42. doi: 10.1016/j.urpr.2016.02.005. Epub 2016 Sep 22.
The treatment paradigm for stage I testicular cancer has changed in the setting of accurate staging, reliable followup and a greater understanding of treatment related side effects. We assessed the influences on management decisions in patients with stage I testicular cancer.
We retrospectively identified 121 patients with stage I testicular cancer who were evaluated at our institution from 1999 to 2013. Sociodemographic characteristics, pathological features and provider specific factors were compared in patients who underwent surveillance vs treatment. Differences in medians and proportions were determined using the Kruskal-Wallis and chi-square tests. Multivariate logistic regression analysis was performed to identify independent predictors of treatment.
A total of 87 patients had stage I nonseminomatous germ cell tumor and 34 had pure seminoma. Patients with nonseminomatous germ cell tumor who were evaluated before 2011 and those seen by urological oncologists were more likely to undergo primary retroperitoneal lymph node dissection (p <0.01). Patients with nonseminomatous germ cell tumor who were evaluated by medical oncologists more often received chemotherapy (p <0.01). For nonseminomatous germ cell tumors treatment was independently associated with advanced tumor stage and lymph node invasion (OR 15.3, 95% CI 3.26-71.95, p = 0.001). In patients with pure seminoma the use of radiation therapy decreased from 40% to 5% after 2010 while surveillance increased from 47% to 74% (p = 0.056) and no recorded variable was predictive of treatment.
Advanced stage and lymph node invasion in patients with stage I nonseminomatous germ cell tumor are drivers of treatment. Management also depends on the specialty of the treating provider, suggesting the possibility of bias during patient counseling. In turn, this suggests the need for patient assessment through a multidisciplinary approach.
在精准分期、可靠随访以及对治疗相关副作用有更深入了解的背景下,I期睾丸癌的治疗模式发生了变化。我们评估了对I期睾丸癌患者管理决策的影响因素。
我们回顾性地确定了1999年至2013年在我们机构接受评估的121例I期睾丸癌患者。对接受监测与治疗的患者的社会人口统计学特征、病理特征和提供者特定因素进行了比较。使用Kruskal-Wallis检验和卡方检验确定中位数和比例的差异。进行多变量逻辑回归分析以确定治疗的独立预测因素。
共有87例患者患有I期非精原细胞性生殖细胞肿瘤,34例患有纯精原细胞瘤。2011年前接受评估的非精原细胞性生殖细胞肿瘤患者以及由泌尿外科肿瘤学家诊治的患者更有可能接受原发性腹膜后淋巴结清扫术(p<0.01)。由肿瘤内科医生评估的非精原细胞性生殖细胞肿瘤患者更常接受化疗(p<0.01)。对于非精原细胞性生殖细胞肿瘤,治疗与肿瘤晚期和淋巴结侵犯独立相关(OR 15.3,95%CI 3.26 - 71.95,p = 0.001)。在纯精原细胞瘤患者中,2010年后放射治疗的使用率从40%降至5%,而监测率从从47%升至74%(p = 0.056),且没有记录到的变量可预测治疗情况。
I期非精原细胞性生殖细胞肿瘤患者的晚期和淋巴结侵犯是治疗的驱动因素。治疗管理还取决于治疗提供者的专业领域,这表明在患者咨询过程中可能存在偏差。反过来,这表明需要通过多学科方法对患者进行评估。